Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.198
Neutral
RSI(14)
20.857
Sell
STOCH(KDJ)(9,3,3)
49.330
Sell
ATR(14)
4.997
High Vlolatility
CCI(14)
-238.911
Oversold
Williams %R
100.000
Oversold
TRIX(12,20)
1.138
Sell
StochRSI(14)
0.000
Sell
Surmodics Inc
SRDX42.980USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
614.53MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Surmodics Inc
Currency: USD Updated: 2025-11-19Key Insights
Surmodics Inc's fundamentals are relatively healthy, Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at max_target_price.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.
Surmodics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
43.000
Target Price
+47.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Surmodics Inc Highlights
StrengthsRisks
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.14% year-on-year.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.95M shares, decreasing 24.21% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.62.
Financial Health
Currency: USD Updated: 2025-11-19Its latest quarterly revenue reached 29.57M, representing a year-over-year decrease of 2.55%, while its net profit experienced a year-over-year decrease of 29.60%.
Score
Financials
7.77
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.35
Operational Efficiency
10.00
Growth Potential
8.11
Shareholder Returns
7.36
Surmodics Inc's Company Valuation
Currency: USD Updated: 2025-11-19The current valuation score of Surmodics Inc is 7.02, ranking industry_rank/industry_total in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 0.00, which is +Inf% below the recent high of 89.87 and +Inf% above the recent low of -445.76.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 77/209
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-11-19The current earnings forecast score of Surmodics Inc is 6.00, ranking industry_rank/industry_total in the Healthcare Equipment & Supplies industry. The average price target for Surmodics Inc is 43.00, with a high of 43.00 and a low of 43.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-19The current price momentum score of Surmodics Inc is 6.65, ranking industry_rank/industry_total in the Healthcare Equipment & Supplies industry.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
33.766
Buy
MA10
33.167
Buy
MA20
30.308
Buy
MA50
30.036
Buy
MA100
31.987
Buy
MA200
30.956
Buy
Institutional Confidence
Currency: USD Updated: 2025-11-19Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
AllianceBernstein L.P.
Oddo BHF Asset Management S.A.S
Hudson Bay Capital Management LP
Qube Research & Technologies Ltd
Readystate Asset Management LP
Geode Capital Management, L.L.C.
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-11-19The current risk assessment score of Surmodics Inc is 3.85, ranking industry_rank/industry_total in the Healthcare Equipment & Supplies industry. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.20
VaR
+3.82%
240-Day Maximum Drawdown
+100.00%
240-Day Volatility
--
Return
Best Daily Return
60 days
+49.72%
120 days
+49.72%
5 years
+49.72%
Worst Daily Return
60 days
-100.00%
120 days
-100.00%
5 years
-100.00%
Sharpe Ratio
60 days
-1.26
120 days
-0.64
5 years
-0.20
Risk Assessment
Maximum Drawdown
240 days
+100.00%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-1.00
3 years
-0.33
5 years
-0.20
Skewness
240 days
-8.53
3 years
-8.78
5 years
-9.20
Volatility
Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
--
5 years
--
Downside Risk-Adjusted Return
120 days
-53.19%
240 days
-53.19%
Maximum Daily Upside Volatility
60 days
+232.91%
Maximum Daily Downside Volatility
60 days
+229.36%
Liquidity
Average Turnover Rate
60 days
+1.39%
120 days
+1.03%
5 years
--
Turnover Deviation
20 days
+61.96%
60 days
+2.37%
120 days
-23.87%
Peer Comparison
Healthcare Equipment & Supplies
Surmodics Inc
SRDX
6.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
UFP Technologies Inc
UFPT
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Surmodics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Surmodics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Surmodics Inc’s performance and outlook.
How do we generate the financial health score of Surmodics Inc?
To generate the financial health score of Surmodics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Surmodics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Surmodics Inc.
How do we generate the company valuation score of Surmodics Inc?
To generate the company valuation score of Surmodics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Surmodics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Surmodics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Surmodics Inc.
How do we generate the earnings forecast score of Surmodics Inc?
To calculate the earnings forecast score of Surmodics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Surmodics Inc’s future.
How do we generate the price momentum score of Surmodics Inc?
When generating the price momentum score for Surmodics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Surmodics Inc’s prices. A higher score indicates a more stable short-term price trend for Surmodics Inc.
How do we generate the institutional confidence score of Surmodics Inc?
To generate the institutional confidence score of Surmodics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Surmodics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Surmodics Inc.
How do we generate the risk management score of Surmodics Inc?
To assess the risk management score of Surmodics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Surmodics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Surmodics Inc.
